Clinical Trials on Anemia, Hemolytic, Congenital Nonspherocytic in Australia

Total 56 results

Rigel Pharmaceuticals

Enrolling by invitation

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Warm Antibody Autoimmune Hemolytic Anemia

Spain, United States, Australia, Norway, Belarus, Germany, Netherlands, Belgium, Austria, Bulgaria, Czechia, France, Georgia, Italy, Russian Federation, Serbia, Ukraine, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers

Thalassemia

Australia
Rigel Pharmaceuticals

Completed

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Warm Antibody Autoimmune Hemolytic Anemia

United States, Spain, Canada, Australia, Norway, France, Belarus, Germany, Netherlands, Belgium, United Kingdom, Austria, Czechia, Georgia, Italy, Russian Federation, Serbia, Ukraine, Romania, Denmark, Hungary, Bulgaria
Sanofi

Active, not recruiting

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
Incyte Corporation

Completed

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia

United States, France, Italy, Austria
Pfizer
Pfizer

Completed

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

Sickle Cell Disease

Australia, United States
Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (VAYHIA)

Warm Autoimmune Hemolytic Anemia (wAIHA)

China, Japan, Spain, Singapore, France, Germany, Taiwan, United States, Italy, India, Malaysia, Argentina, Hungary, Israel, Australia, Thailand, United Kingdom, Romania
Alexion Pharmaceuticals

Completed

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Atypical Hemolytic-Uremic Syndrome

United Kingdom, Belgium, United States, Germany, Italy, France, Netherlands, Australia, Canada
Incyte Corporation

Active, not recruiting

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)

Warm Autoimmune Hemolytic Anemia (wAIHA)

Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion Pharmaceuticals

Completed

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS (aHUS)

Atypical Hemolytic Uremic Syndrome

France, United States, Austria, Germany, United Kingdom
Alexion Pharmaceuticals

Terminated

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment (EVIDENCE)

Atypical Hemolytic Uremic Syndrome

United States, Australia, Germany, United Kingdom
Alexion Pharmaceuticals

Terminated

aHUS Observational Long Term Follow-Up (LTFU)

Atypical Hemolytic Uremic Syndrome

France, Canada, United States, Belgium, Italy, United Kingdom, Netherlands, Australia, Austria, Germany, Sweden, Switzerland
Alexion
Syneos Health

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Atypical Hemolytic-Uremic Syndrome

France, Germany, Israel, Italy, United Kingdom, Canada, United States, Australia, Belgium, Denmark, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Cold Agglutinin Disease | Warm Autoimmune Hemolytic Anemia

United States, Canada, Australia, Turkey
bluebird bio

Completed

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

β-thalassemia Major

United States, Australia, Thailand
Kezar Life Sciences, Inc.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP (MARINA)

Immune Thrombocytopenia | Autoimmune Hemolytic Anemia

Poland, United States, Australia, Italy, Russian Federation
Ionis Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Beta Thalassemia Intermedia

Australia, Thailand, Greece, Lebanon, Turkey
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Celgene

Completed

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Myelodysplastic Syndromes | Beta-thalassemia

Austria
bluebird bio

Active, not recruiting

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

Transfusion-dependent Beta-Thalassemia

United States, France, United Kingdom, Australia, Thailand, Italy, Germany, Greece
FerroKin BioSciences, Inc.

Completed

Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload

Beta-thalassemia | Transfusional Iron Overload

United States, Australia, Thailand
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)

Beta-Thalassemia | Erythrocyte Transfusion

United States, Israel, Australia, Turkey, Taiwan, Malaysia, United Kingdom, Canada, Thailand, France, Lebanon, Italy, Bulgaria, Greece, Tunisia
Bioverativ, a Sanofi company
Assign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute and other collaborators

Completed

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders (BIVV009-01)

End-stage Renal Disease (ESRD) | Cold Agglutinin Disease (CAD) | Bullous Pemphigoid (BP) | Warm Autoimmune Hemolytic Anemia (WAIHA)

Austria
Alexion

Completed

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Germany, Spain, Switzerland, Netherlands, Canada, Austria
University of Regensburg

Recruiting

A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

Sickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin S

Germany, Austria
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)

Atypical Hemolytic Uremic Syndrome

China, Korea, Republic of, Austria, Taiwan, Greece, Czechia, United States, Japan, Brazil, United Kingdom, India, Slovakia, Slovenia
Novartis

Completed

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Myelodysplastic Syndromes | Hemoglobinopathies | Diamond-Blackfan Anemia | Transfusional Iron Overload | Other Inherited or Acquired Anaemia | MPD Syndrome | Other Rare Anaemias

Australia
Novartis Pharmaceuticals

Completed

An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)

Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia

Australia
La Jolla Pharmaceutical Company

Terminated

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Beta-Thalassemia

Australia, Thailand, United States, Greece, Italy, Lebanon, Turkey, United Kingdom
Medical University of Graz

Active, not recruiting

Severe Immune Cytopenia Registry Www.Sic-reg.Org (sic-reg)

Primary Immunodeficiency | Immune Thrombocytopenia | Autoimmune Hemolytic Anemia | Evans Syndrome

Austria
Bioverativ, a Sanofi company

Completed

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza)

Cold Agglutinin Disease

United States, United Kingdom, Israel, Australia, Spain, Austria, Germany, France, Belgium, Japan, Canada, Netherlands, Italy, Norway
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
Bioverativ, a Sanofi company

Completed

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)

Agglutinin Disease, Cold

United States, Israel, Australia, Spain, Austria, Germany, Belgium, France, Canada, Italy, Japan, Norway, Netherlands, United Kingdom
Swedish Orphan Biovitrum

Suspended

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Cold Agglutinin Disease

Spain, Belgium, Norway, United States, Japan, United Kingdom, Netherlands, Canada, Hungary, Austria, Finland, Georgia, Germany, Italy
Celgene

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

United States, Japan, Israel, United Kingdom, Turkey, Greece, Netherlands, France, Australia, Belgium, Bulgaria, Canada, Germany, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, China, Lebanon
Novartis Pharmaceuticals

Recruiting

CINC424A2X01B Rollover Protocol

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Thalassemia | Graft Versus Host Disease

Korea, Republic of, Belgium, Italy, Japan, Germany, Australia, Bulgaria, Chile, China, Denmark, Greece, Hungary, Israel, Lebanon, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Thailand, India, Mexico, Turkey, Fran...
Sanofi

Recruiting

Cold Agglutinin Disease Real World Evidence Registry (CADENCE)

Cold Agglutinin Disease (CAD) | Cold Agglutinin Syndrome (CAS)

United States, Austria, France, Italy, Germany, Japan, Spain, United Kingdom
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Australia
BioCryst Pharmaceuticals

Completed

First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Austria, South Africa
Alexion Pharmaceuticals

Completed

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Hemoglobinuria, Paroxysmal

United States, Australia, Belgium, Canada, Germany, Italy, United Kingdom, France, Ireland, Netherlands, Sweden, Switzerland
Alexion Pharmaceuticals

Completed

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Hemoglobinuria, Paroxysmal

United States, United Kingdom, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland
BioCryst Pharmaceuticals

Active, not recruiting

A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

United Kingdom, Austria, South Africa
Alexion Pharmaceuticals

Completed

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Hemoglobinuria, Nocturnal

United States, Australia, Belgium, Canada, Germany, Italy, Spain, Sweden, United Kingdom, France, Ireland, Netherlands
Alexion Pharmaceuticals

Completed

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Paroxysmal Nocturnal Hemoglobinuria | PNH

Australia, France, United Kingdom, Belgium, Germany, Netherlands, Ireland, United States, Switzerland, Italy
Ra Pharmaceuticals

Completed

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Australia, Canada, Denmark, Finland, Germany, Hungary, New Zealand
University Hospital Freiburg

Completed

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Pearson Marrow-pancreas Syndrome | Shwachman-diamond Syndrome

Spain, Germany, Switzerland, Austria, Netherlands, Italy, Czech Republic, Belgium, Denmark, Ireland
Alexion

Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Ra Pharmaceuticals, Inc.

Terminated

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Australia, Canada, Finland, Germany, Hungary, New Zealand, United Kingdom

Clinical Trials on Anemia, Hemolytic, Congenital Nonspherocytic in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations